Table I.
Demographic and clinical characteristics of NMSC cases (n = 124)
| n (%) |
|||
|---|---|---|---|
| Characteristics | Patients with SCC (n = 40)* | Patients with BCC (n = 95)* | Overall (n = 124) |
| Age at diagnosis in y (median, range) | 14.1 (2.2–19.8) | 12.2 (0.9–19.8) | 13.2 (0.9–19.8) |
| Follow-up time after initial skin cancer in years† [n, median (range)] | n = 36, 4 (0–20.7) | n = 92, 3.3 (0.0–22.1) | n = 118, 3.4 (0.0–22.1) |
| Age at diagnosis | |||
| 0–5 y | 6 (15) | 12 (13) | 15 (12) |
| 6–10 y | 5 (13) | 30 (32) | 33 (27) |
| 11–15 y | 17 (43) | 29 (31) | 44 (35) |
| >15 y | 12 (30) | 24 (25) | 32 (26) |
| Sex | |||
| Male | 18 (45) | 44 (46) | 58 (47) |
| Female | 22 (55) | 51 (54) | 66 (53) |
| Race | |||
| White | 22/33 (67) | 56/74 (76) | 75/99 (76) |
| Black | 2/33 (6) | 5/74 (7) | 5/99 (5) |
| Hispanic | 6/33 (18) | 7/74 (9) | 11/99 (11) |
| Asian | 1/33 (3) | 4/74 (5) | 4/99 (4) |
| Middle-Eastern | 2/33 (6) | 1/74 (1) | 3/99 (3) |
| American Indian | 0/33 (0) | 1/74 (1) | 1/99 (1) |
| Unknown | 7 | 21 | 25 |
| Life status at last follow-up | |||
| Dead | 4 (10) | 3 (3) | 6 (5) |
| Alive | 35 (88) | 87 (92) | 112 (90) |
| Unknown | 1 (2) | 5 (5) | 6 (5) |
| Predisposing genetic conditions | 18 (45) | 47 (49) | 55 (44) |
| Basal cell nevus syndrome | 1 (3) | 34 (36) | 34 (27) |
| Bloom syndrome | 0 | 1 (1) | 1 (1) |
| Dyskeratosis congenita | 2 (5) | 0 (0) | 2 (2) |
| Epidermolysis bullosa | 1 (3) | 0 (0) | 1 (1) |
| Incontinentia pigmenti | 1 (3) | 0 (0) | 1 (1) |
| Primary immunodeficiency | 2 (5) | 1 (1) | 2 (2) |
| Xeroderma pigmentosum | 11 (28) | 11 (12) | 14 (11) |
| Predisposing skin lesions | 3 (8) | 10 (11) | 12 (10) |
| Chronic ulcer | 1 (3) | 0 (0) | 1 (1) |
| Epidermolysis bullosa | 1 (3) | 0 (0) | 1 (1) |
| Morphea | 1 (3) | 0 (0) | 1 (1) |
| Nevus sebaceus | 0 (0) | 9 (9) | 9 (7) |
| Wart | 1 (3) | 1 (1) | 1 (1) |
| Iatrogenic exposures | 14 (35) | 25 (26) | 36 (29) |
| Prolonged immunosuppression | 12 (30) | 5 (5) | 16 (13) |
| Radiation therapy | 5 (13) | 19 (20) | 21 (17) |
| Chemotherapy | 3 (8) | 19 (20) | 21 (17) |
| Voriconazole use | 6 (15) | 2 (2) | 7 (6) |
| Other pertinent medical history | |||
| Prior oncologic diagnosis | 7/38 (18) | 24/92 (26) | 28/120 (23) |
| HSCT | 6 (15) | 8 (8) | 13/124 (10) |
| Organ transplant | 6 (15) | 2 (2) | 7/124 (6) |
| No identifiable risk factors‡ | 12 (30) | 26 (27) | 37/124 (30) |
*
Groups are not mutually exclusive. Denominators are 40 for the SCC group, 95 for the BCC group, 11 for SCC and BCC group, 9 for the melanoma group unless otherwise specified.
†
Censored patients are those who have not died at the time of last contact.
‡
No identifiable risk factors: Defined as having no predisposing genetic conditions, no predisposing skin lesions, and no iatrogenic exposures.